Dosing & Uses
Dosage Forms & Strengths
tablet
- 250mg
- 500mg
Type 2 Diabetes
100-250 mg PO qDay or q12hr
Increase dose by 100-250 mg/day at weekly intervals to response; not to exceed 1 g/day
Fasting blood sugar <200 mg/dL
- 100 mg/day PO
Fasting blood sugar >200 mg/dL
- 250 mg/day PO
Malnurished, underweight, not eating properly, or elderly
- 100 mg/day PO
Safety and efficacy not established
Type 2 diabetes
100-250 mg PO qDay or q12hr
Increase dose by 100-250 mg/day at weekly intervals to response; not to exceed 1 g/day
Fasting blood sugar <200 mg/dL
- 100 mg/day PO
Fasting blood sugar >200 mg/dL
- 250 mg/day PO
Malnurished, underweight, not eating properly, or elderly
- 100 mg/day PO
Interactions
Interaction Checker
No Results

Contraindicated
Serious - Use Alternative
Significant - Monitor Closely
Minor

Adverse Effects
Frequency Not Defined
Hypoglycemia
Dermatologic reactions
Heartburn
Dizziness
Vertigo
Anorexia
Constipation
Nausea/vomiting
Cholestatic jaundice and hepatitis may occur rarely which may progress to liver failure
Warnings
Contraindications
Hypersensitivity, sulfa allergy
Type I diabetes, diabetic ketoacidosis
Cautions
Patients with hypoglycemia, stress due to infection, fever, trauma, or surgery
May cause loss of glycemic control due to secondary failure
First generation sulfonylurea
Intermediate acting agent
Tolazamide demonstrates weak diuretic effect
Pregnancy & Lactation
Pregnancy Category: C
Lactation: not known if crosses into breast milk, avoid
Pregnancy Categories
A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk. C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done. D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk. X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist. NA: Information not available.Pharmacology
Mechanism of Action
Initial effect is to increase beta-cell insulin secretion
May also decrease rate of hepatic glucose production, increases insulin receptor sensitivity, and increases number of insulin receptors
Pharmacokinetics
Half-Life: 7 hr
Duration: 14-24 hr
Onset: 20 minutes
Protein binding: 94%
Peak hypoglycemic effect: 4-6 hr
Metabolism: Hepatic to less active metabolites
Metabolites: Inactive metabolites
Excretion: Urine (85%); feces (7%)
Images
Patient Handout
Formulary
Adding plans allows you to compare formulary status to other drugs in the same class.
To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.
Adding plans allows you to:
- View the formulary and any restrictions for each plan.
- Manage and view all your plans together – even plans in different states.
- Compare formulary status to other drugs in the same class.
- Access your plan list on any device – mobile or desktop.